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Purpose: To describe changes in knowledge of cervical cancer prevention, human papillomavirus (HPV), and HPV
vaccination among women at high risk for cervical cancer in the ﬁrst ﬁve years after introduction of HPV
vaccination.
Methods: In 2007, 2008–9, and 2011, women in a multicenter U.S. cohort study completed 44-item self-report
questionnaires assessing knowledge of cervical cancer prevention, HPV, and HPV vaccination. Results across
time were assessed for individuals, and three study enrollment cohorts were compared. Knowledge scores
were correlated with demographic variables, measures of education and attention, and medical factors.
Associations were assessed in multivariable models.
Results: In all, 974 women completed three serial questionnaires; most were minority, low income, and current
or former smokers. The group included 652 (67%) HIV infected and 322 (33%) uninfected. Summary knowledge
scores (possible range 0–24) increased from2007 (12.8, S.D. 5.8) to 2008–9 (13.9, S.D. 5.3, P b 0.001) and to 2011
(14.3, S.D. 5.2, P b 0.0001 vs 2007 and b0.04 vs 2008–9). Higher knowledge scores at ﬁrst and follow-up
administration of questionnaires, higher income, and higher education level were associated with improved
knowledge score at third administration. Women not previously surveyed had scores similar to those of the
longitudinal group at baseline.
Conclusion: Substantial gaps in understanding of HPV and cervical cancer prevention exist despite years of health
education. While more effective educational interventions may help, optimal cancer prevention may require
opt-out vaccination programs that do not require nuanced understanding.© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Indigent and minority women and those with multiple sexual part-
ners are at particular risk for cervical cancer. These are also risk factors
for infection with the human immunodeﬁciency virus (HIV), making
HIV seropositivity a useful marker for cervical cancer risk. HIV increases
HPV infections, abnormal Paps, and cervical cancer (Massad et al.,
2008). Screening and precursor treatment reduce cancer risk even forncology, 4911 Barnes-Jewish
1 314 362 2893.
rt Massad).
. This is an open access article underwomen with HIV (Massad et al., 2009). However, cervical cancer pre-
vention is complex, involving HPV vaccination, screenings, triage with
HPV tests and colposcopy, and therapy. High risk women including
those with HIV are often noncompliant (Cejtin et al., 1999). Under-
standingwhat womenwith HIV know about cervical cancer prevention
may offer insights into how educational efforts might target high risk
women.
Previous research involving a national cohort of women with HIV
and comparison HIV-uninfected women demonstrated knowledge
gaps related to risk factors for and consequences of HPV infection.
These women also have limited understanding of cervical cancer pre-
vention methods (Massad et al., 2010a, 2010b). Knowledge correlatedthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
Baseline demographic and medical characteristics of women who completed question-
naires at three consecutive surveys (n = 974). n (%).
HIV+
N = 652
HIV−
N= 322
P-valuea
Age at baseline interview (years)
b30 5 (0.8) 30 (9.3) b0.0001
30–39 116 (17.8) 85 (26.4)
40–49 268 (41.1) 110 (34.2)
50+ 263 (40.3) 97 (30.1)
Ethnicity
Non-Hispanic African American 418 (64.1) 205 (63.6) 0.0054
Hispanic 115 (17.7) 78 (24.2)
Non-Hispanic White 94 (14.4) 25 (7.8)
Other 25 (3.8) 14 (4.4)
Average annual household income
(n = 941)
b=$6000 78 (12.3) 59 (19.3) 0.0011
$6001–$12,000 224 (35.3) 77 (25.2)
$12,001–$18,000 69 (10.8) 45 (14.7)
$18,001+ 264 (41.6) 125 (40.8)
Education level (n = 973)
Less than high school 213 (32.7) 109 (34.0) 0.3743
Completed high school 201 (30.8) 109 (34.0)
Some college/college degree 238 (36.5) 103 (32.0)
Site/location
Bronx 101 (15.5) 60 (18.6) 0.0017
Brooklyn 201 (30.8) 69 (21.4)
Washington DC 97 (14.9) 44 (13.7)
Los Angeles 72 (11.0) 58 (18.0)
San Francisco 87 (13.4) 54 (16.8)
Chicago 94 (14.4) 37 (11.5)
Alcohol use
Abstainer 371 (56.9) 133 (41.3) b0.0001
Light (b3 drinks/week) 200 (30.7) 111 (34.5)
Moderate/heavy (3+ drinks/week) 81 (12.4) 78 (24.2)
Current smoker
Current user 235 (36.0) 143 (44.4) 0.0197
Former user 226 (34.7) 107 (33.2)
Never 191 (29.3) 72 (22.4)
Injection drug use status
Current user 4 (0.6) 8 (2.5) 0.0361
Former user 42 (6.5) 24 (7.5)
Never 606 (92.9) 290 (90.0)
Non-injection drug use status
Current user 119 (18.3) 94 (29.2) b0.0001
Former user 242 (37.1) 132 (41.0)
Never 291 (44.6) 96 (29.8)
Lifetime nadir CD4 lymphocyte count
(cells/mm3) (n = 626)
b200 200 (32.0)
200–500 349 (55.7)
N500 77 (12.3)
CD4 lymphocyte count (cells/mm3)
at visit (n = 642)
b200 75 (11.7)
200–500 197 (30.7)
N500 370 (57.6)
a By chi-square test.
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tion, better reading skills, and prior abnormal Pap (Massad et al.,
2010a). Knowledge had little impact on colposcopy compliance
(Massad et al., 2012), perhaps because knowledge remained suboptimal
despite improving after an educational intervention (Massad et al.,
2010b).
Since vaccine introduction in 2006, marketing and media coverage
have exposed many U.S. women to information about cervical cancer,
HPV, and HPV vaccination (Kelly et al., 2009; Gottlieb, 2013), but the
impact of these messages on high risk women is unclear. This analysis
extends prior research by exploring trends over time in knowledge
and attitudes. In addition, we assessed knowledge in a cohort of
women without prior experience with our questionnaire enrolled
after HPV vaccine release.
Methods
This investigation was a part of theWomen's Interagency HIV Study
(WIHS), an ongoingU.S. multicenter prospective cohort investigation of
HIV infection among HIV seropositive women and seronegative com-
parison women at risk for HIV. Protocols, recruitment processes, proce-
dures, and baseline results have been described (Barkan et al., 1998;
Bacon et al., 2005). Enrollment began with 2623 women in 1994–5 at
6 study consortia (Bronx, Brooklyn, Chicago, Los Angeles, San Francisco,
andWashington, D.C.). To remain reﬂective of the demographics of the
U.S. HIV epidemic, the cohort was expanded by 1143 additional women
during 2001–2002 (Bacon et al., 2005) and by 371 more in 2011–2012.
This analysis compares information from three cross-sectional ques-
tionnaires administered in English April–October, 2007 (baseline),
October, 2008–April, 2009 (follow-up), and April–October, 2011 (third
administration). Results of the ﬁrst two iterations have been described
(Massad et al., 2009, 2010b). Following baseline administration,
women were provided with correct answers and explanations as an
educational intervention to assess its impact on knowledge.
The 44-item questionnaire included items related to knowledge
of HPV, cervical cancer risks, HPV vaccine, and abnormal Pap tests. A
change score analysis, using the paired t-test, was conducted to assess
whether and to what extent individual knowledge scores improved be-
tween baseline and follow-up. Analysis of covariance models examined
change in knowledge between baseline and follow-up. Independent
variables included baseline score, HIV status, and demographic and
medical characteristics including age at questionnaire administration,
ethnicity, education by study entry, and household income. Each
variable was evaluated for ﬁt using the type III SS value and p-value
and was included in analyses if p-value b 0.05. Final models used the
PROC Generalized Linear Models (GLM) procedure in SAS software 9.2
(SAS Institute Inc., Cary, NC). A separate analysis was conducted on
only the third survey administration to evaluate for knowledge differ-
ences among recruitment waves. Chi-square tests compared recruit-
ment cohorts by knowledge questions and ﬁnal models were ﬁt using
similar techniques for the longitudinal analysis including recruitment
wave as an independent variable.
Results
Of 1451women completing questionnaires in 2007, 974 (67%) com-
pleted three serial questionnaires. Of these, 652 (67%) were completed
by HIV seropositive and 322 (33%) by seronegative women. Risk factors
for cervical cancer includingminority ethnicity, low annual income, and
current or former smoking history were present in the majority of par-
ticipants (Table 1). When compared to HIV seronegative women, HIV
seropositive women were older, more likely to be non-Hispanic white,
and less likely to currently use alcohol, tobacco, or drugs.
Individual component results of questionnaires across the three
recruitment waves are presented in Tables 1–3, Supplemental digital
content. Mean knowledge scores increased across administrations,from 12.8 (S.D. 5.8) at baseline to 13.9 (5.3) at follow-up (P b 0.0001)
to 14.3 (S.D. 5.2) at third administration (P b 0.0001 vs baseline and
b0.04 vs follow-up). As scores are out of a possible 24, even improved
later scores reﬂect limited knowledge. Lower baseline scores of HIV se-
ronegative women (11.7 with S.D. 6.0) versus HIV seropositive women
(13.3 S.D. 5.7, P b 0.0001) were eliminated by the third questionnaire
administration (13.9 with S.D. 5.3 among HIV uninfected vs 14.4 with
S.D. 5.1 among HIV infected women, P = 0.12). No improvement in
knowledge of HPV vaccine, its indications, or its target population was
observed between the follow-up and third questionnaire administra-
tions. Although small increases in knowledge were seen, at the third
questionnaire administration only 56% of all women studied knew
that Pap testing checked the cervix, 46% knew it should be repeated at
1–3 year intervals for women with HIV. In contrast, 83% of all women
studied knew that annual Pap testing was indicated for women with
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precancer and cancer, 74% knew that HPV is a sexually transmitted virus
that causes genital warts and cancers, and 78% knew that women with
HPV are at higher risk for cancer. These results wereminimally changed
from the follow-up administration of the questionnaire.
Independent factors associated with an improvement in knowledge
score at the third, previously unreported administration of the survey
included higher knowledge scores at ﬁrst and follow-up administration
of questionnaires, higher income, and higher education level (Table 2).
There was also a signiﬁcant difference in knowledge score by site.
R-squared for this model was 0.35, indicating that these factors ex-
plained approximately one third of themagnitude of change. HIV status
was not signiﬁcant after controlling for these factors, nor was drug use.
A cross-sectional analysis of the third administration of the survey
evaluated knowledge among women in a recently enrolled cohort.
The survey was completed by 1968 women (979 cohort 1, 734 cohort
2, 255 cohort 3). Overall there was a higher percentage of HIV seropos-
itive women in the third compared to the ﬁrst and second cohorts
(82.5% vs 74.6% and 63.5%, P b 0.0001). The average age in the ﬁrst, sec-
ond and third cohorts respectivelywere 51.4, 41.1, and 44.1 years. In ad-
dition, compared to the ﬁrst and second cohorts, the third cohort was
more likely to be non-Hispanic African-American, to have lower
income, to report alcohol or drug use, and to be a current smoker.
There also were differences in CD4 counts below 200 cells/mm3: cohort
1, 63.4%, cohort 2, 22.3%, cohort 3, 30.5, P b 0.0001. Although mean
scores did not differ between ﬁrst and second enrollment cohorts
(14.0 (S.D. 5.2) vs 13.8 (5.4), P = 0.27), scores were lower for the
third (12.5 (5.8), P = 0.0001 vs the ﬁrst cohort and P = 0.002 vs the
second cohort). Speciﬁc differences among cohorts are presented in
Tables 1–3 of Supplemental digital content, but differences were pres-
ent across all components of the questionnaire. Only 50–60% of
women in all cohorts believed cervical cancer is preventable. Only
about 60% of women in the ﬁrst and second cohorts said that they had
heard of the HPV vaccine (Table 3, Supplemental digital content), al-
though all had been informed during previous iterations of the ques-
tionnaire; only 43% of women in the third cohort said that they had
heard of the HPV vaccine (P b 0.0001). Despite this, some three fourths
of all cohorts knew that the HPV vaccine was targeted to adolescentsTable 2
Analysis of Covariance Models assessing factors associated with cervical cancer prevention
controlled for study site.
Model for women completing a
administrations N = 974
Adjusted R2 0.35
F-value 46.98⁎⁎⁎
Predictor variables
Intercept 8.94 (7.47, 10.40)⁎⁎⁎
Total baseline score (1st) 0.27 (0.22, 0.33)⁎⁎⁎
Total follow-up score (2nd) 0.28 (0.22, 0.34)⁎⁎⁎
Recruitment cohort (vs 3rd cohort)
Cohort 1
Cohort 2
HIV seropositive (vs negative) −0.18 (−0.75, 0.39)
Age less than 50 (vs 50+ years)
Ethnicity (vs White NH)
Non-Hispanic African American
Hispanic
Other
Education (vs College)
Less than high school −0.88 (−1.57,−0.18)⁎
Completed high school −0.10 (−0.76, 0.57)
Income b $18,000 (vs N $18,000) −0.82 (−1.41,−0.24)⁎⁎
Drug use (vs never)
Former user
Current user
⁎ p b= 0.05.
⁎⁎ p b= 0.01.
⁎⁎⁎ p b= 0.001.and teens. Furthermore, 71% of both the ﬁrst and second enrollment co-
horts knew that the vaccine prevented abnormal Pap tests and cervical
precancer and cancer, though only 62% of women in the third cohort
knew this (P = 0.01). A multivariable model demonstrated that being
in the ﬁrst or second recruitment cohort wave was associated with a
higher knowledge score compared to those recruited in the last wave.
In addition, beingHIV positive or a former or current drug user, younger
age, having a higher income or education level, and being a white non-
Hispanic respondent was associated with higher knowledge scores
(Table 2).Discussion
Cervical cancer disproportionately afﬂicts poor and minority U.S.
women, largely because they fail to receive screening. HPV vaccination
lowers risk, but the U.S. vaccination program requires parents to elect
vaccination for their children, which in turn requires understanding of
risks and indications.
Among women at high cervical cancer risk, knowledge of cervical
cancer prevention has improved, but gaps remain. Women newly en-
rolled into our cohort had knowledge scores lower than those of previ-
ously enrolled women but similar to baseline scores in prior cohorts, as
previous administrations of the questions and an educational interven-
tion involving provision of their answers improved knowledge (Massad
et al., 2010b). Nevertheless, appreciation of cervical cancer prevention
processes among similar women outside the study is likely to be less
than optimal to support informed screening compliance and election
of HPV vaccination for themselves and their children.
Our results are similar to others', though our study includes longitu-
dinal results. Kelly and colleagues showed that despite a sharp increase
in knowledge of the link between HPV and cervical cancer after vaccine
introduction, knowledge leveled off below 60% (Kelly et al., 2009).
Joseph and associates found that only half of low-income women sur-
veyed in 2007–2012 knew that HPV causes cervical cancer and that
knowledge deﬁcits were greater among minority women (Joseph
et al., 2014). Strohl et al. found low knowledge scores among Chicago
African American women (Strohl et al., 2014).knowledge score at third survey administration among high risk women. Both models
ll 3 survey Model for women who completed the third survey
administration N = 1968
0.10
18.2⁎⁎⁎
15.69 (14.60, 16.79)
1.12 (0.36, 1.88)⁎⁎
0.96 (0.20, 1.71)⁎
0.52 (−0.003, 1.03)
0.71 (0.17, 1.24)⁎⁎
−1.76 (−2.52,−1.00)⁎⁎⁎
−1.50 (−2.36,−0.64)⁎⁎⁎
−1.61 (−2.95,−0.27)⁎⁎
−2.61 (−3.20,−2.03)⁎⁎⁎
−0.96 (−1.55,−0.37)⁎⁎⁎
−1.27 (−1.79,−0.75)⁎⁎⁎
0.85 (0.30, 1.39)⁎⁎
0.61 (−0.01, 1.22)
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olescents and young uninsured women are less likely to be vaccinated
(Pierce Campbell et al., 2012). Inadequate appreciation of vaccine bene-
ﬁts and risks pose a barrier to vaccination (Donadiki et al., 2014). Mes-
sages targeted to poor and minority women are needed to improve
vaccination rates, and our results suggest that these messages may
have to clarify very basic concepts.
Inclusion of women with HIV was a strength of the study. Such
women are at particular risk, in part because of immunosuppression
but also because they have multiple cancer risk factors such as smoking
and multiple sexual partners. Other strengths include serial survey ad-
ministration and the multisite cohort.
This studywas limited by several factors.Womenwere participating
in semiannual Pap screening as part of theWIHS, sowe could not assess
impact of knowledge on screening or vaccination. Screening guidelines
changed after the 2011 administration of our questionnaire, and current
understanding about screening intervals and tests might not reﬂect
these new recommendations. Most study women were older than the
target age for HPV vaccination, and we did not assess the impact of
knowledge or attitudes on vaccination rates among young relatives
whomight be vaccination candidates.We could not determinewhether
differences between prior andmost recent enrollees were due to longer
experience with cervical cancer prevention in WIHS, familiarity with
questionnaires, or other factors distinguishing enrollment cohorts.
However, our ﬁnding that knowledge of cervical cancer prevention
was lower among newest recruits indicates that passive learning from
media, family and friends, and health care providers in recent years is
insufﬁcient. Finally, women enrolled in WIHS may be selected. Howev-
er, women outside frequent care and women who have not dedicated
themselves to a decade-long study are likely to be even less informed
about cervical cancer prevention than participants in our study.
Not all items assessed in our question setmay directly inﬂuence pre-
vention and treatment behaviors. For instance, while women should be
aware of guidelines on Pap frequency, knowing diet does not impact
cervical cancer riskmay be less important. Further research to better de-
ﬁne determinants of HPV prevention and cervical cancer detection/
treatment behaviors and to identify subgroups at greater risk based on
these determinantsmay aid in designing and disseminatingmore effec-
tive strategies to improve these outcomes.
Misperceptions about cervical cancer prevention remain common
among the largely poor andminoritywomen in our study.While specif-
ic educational efforts may improve understanding and prevention be-
havior, school based or mandatory HPV vaccination may have greater
long-term impact. Opt-out approaches may yield better vaccination
rates than opt-in approaches that require weighing of vaccine beneﬁts
and risks. Long-term progress against cervical cancer may require addi-
tional messages on providing women at high risk for cervical cancer
with the understanding they need to enroll their children in routine
HPV vaccination programs.
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